Collegium Pharmaceutical (COLL) Q2 2026 earnings review
ADHD Growth Masks Cracks in the Legacy Pain Portfolio
Collegium delivered 6% top-line growth in Q2, driven by a 41% surge in JORNAY PM and the successful initial integration of AZSTARYS. However, GAAP net income swung to a $15.1M loss due to $24.1M in acquisition-related costs. More concerningly, the cash-generating Pain Portfolio reversed course, dropping 9% YoY. Management was forced to cut full-year revenue and Adjusted EBITDA guidance due to severe net pricing pressure on the Nucynta authorized generic, signaling that the company's legacy cash engine is sputtering faster than expected.
🐂 Bull Case
JORNAY PM revenue growth accelerated to 41% YoY (reaching $46.1M), driven by record prescriptions and a prescriber base exceeding 30,000. It remains a highly durable growth engine.
The newly acquired AZSTARYS contributed $12.9M in just a partial quarter (May 12 - June 30). Management raised its full-year guidance to $65-$75M, validating the strategic rationale of the acquisition.
🐻 Bear Case
The authorized generic (AG) strategy for Nucynta is facing severe headwinds. Lower net pricing forced a $40M cut to the midpoint of FY26 total revenue guidance, undermining the portfolio's cash durability.
Xtampza ER revenues fell 14% YoY to $45.0M. After growing 7% in Q1, this sudden reversal adds broader concern that the entire pain portfolio is eroding.
⚖️ Verdict: ⚪
Mixed. While the successful pivot toward the ADHD market (JORNAY PM + AZSTARYS) is executing flawlessly, the deteriorating pain portfolio and resulting guidance cut introduce material cash flow and deleveraging risks.
Key Themes
Guidance Cut Driven by Nucynta Pricing
Management lowered FY26 Product Revenues guidance by $40M at the midpoint (to $825-$855M) and Adjusted EBITDA by $30M (to $445-$470M). The explicit driver is lower-than-expected revenue from the Nucynta authorized generic (AG) due to lower net pricing. Nucynta franchise revenue plummeted 24% YoY in Q2 to $35.2M. This breaks the prior narrative that the AG strategy would successfully maximize and defend franchise value.
JORNAY PM Adoption Accelerating
JORNAY PM continues to outperform. Q2 prescriptions grew 13.1% YoY, pushing revenue up 41% YoY to $46.1M. The prescriber base expanded by 17.6% to an all-time high of over 30,000 healthcare providers. Management reaffirmed FY26 guidance of $190-$200M, indicating confidence in sustained momentum heading into the critical back-to-school season.
AZSTARYS Demonstrates Immediate Traction
The AZSTARYS acquisition closed in mid-May and immediately contributed $12.9M in partial-quarter revenue. The complementary positioning (rapid onset vs JORNAY PM's awakening efficacy) appears to be working, prompting management to raise AZSTARYS FY26 revenue guidance from $60-$70M to $65-$75M.
Xtampza ER Reversing Course
Beyond Nucynta, Xtampza ER posted a surprising 14% YoY decline to $45.0M. This marks a sharp deceleration from Q1's 7% YoY growth. If both Nucynta and Xtampza are facing simultaneous pressure, the foundational cash flow supporting the company's debt obligations becomes much less stable.
Elevated Debt Profile Post-Acquisition
Following the $650M AZSTARYS acquisition ($350M cash + $300M debt), Collegium's balance sheet has fundamentally changed. Term notes payable surged to $852.8M (up from $571.1M at year-end), bringing total debt to over $1.09B. Concurrently, cash and marketable securities dropped from $442.6M in Q1 to $129.5M. The company must now rely heavily on JORNAY/AZSTARYS growth to deleverage, leaving less margin for error.
Other KPIs
Reversing from a $12.0M profit a year ago. The loss was entirely driven by $24.1M in acquisition-related expenses and higher intangible asset amortization ($63.0M vs $55.5M) tied to the AZSTARYS purchase.
Stable. Grew 8% YoY despite the GAAP net loss, highlighting that the underlying cash-generation capacity of the core business remains intact, even as it fell short of management's original full-year expectations.
Accelerating. Up 10% YoY, making it the sole bright spot within the struggling Pain Portfolio. This brand strength helps partially offset the steep declines in Nucynta and Xtampza.
Guidance
Decelerating. Lowered from the prior $865 - $895M range. Driven entirely by lower net pricing expectations for the authorized generic versions of Nucynta.
Decelerating. Cut from $475 - $500M. The $30M reduction at the midpoint directly reflects the flow-through impact of the Nucynta pricing pressure on gross margins.
Accelerating. Raised from the initial $60 - $70M target provided when the acquisition was announced, signaling strong early integration and sales force execution.
Stable. Unchanged, implying ~31% YoY growth at the midpoint. Management continues to view this as the primary organic growth engine.
Key Questions
Nucynta AG Pricing Floor
The guidance cut implies a structural shift in Nucynta AG pricing. Where is the floor on net pricing, and how does this alter the long-term durability models for the Pain Portfolio?
Xtampza ER Dynamics
Xtampza ER flipped from 7% growth in Q1 to a 14% decline in Q2. Was this driven by inventory destocking, loss of formulary access, or underlying prescription demand destruction?
Deleveraging Timeline
With the cut to Adjusted EBITDA and a significantly higher debt load post-AZSTARYS, does the company still expect to return to a sub-2.0x net leverage ratio by year-end?